B7-H4-Targeting Antibody-Drug Conjugate, LNCB74, Gets Green Light for Clinical Trials for Solid Tumors
/0 Comments/in Clinical Trial, Phase 1/by MaxNew Drug Receives FDA Clearance to Begin Clinical Trials
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxMatching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins
/0 Comments/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by MaxPromising Results for B7-H3 Antibody-Drug Conjugate in Advanced Solid Tumors (including metastatic castration resistant prostate cancer)
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxMetformin Shows Promise in Reducing Side Effects of Hormone Therapy in Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxJanux Therapeutics Announces 100% Response in Phase 1a Results for JANX007 in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxTruqap Shows Promise in Treating a Subtype of Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxFDA Accepts Darolutamide Plus ADT sNDA for mHSPC Treatment
/0 Comments/in Clinical Trial, FDA approvals, Metastatic, Phase 3/by MaxPhase III Trial for Metastatic Castration-Resistant Prostate Cancer of an EZH2 inhibitor
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxTags
abiraterone acetate ADC ADT alphafold androgen deprivation therapy antibody-drug conjugate apalutamide artificial intelligence ATM bispecific antibody BRCA cancer immunotherapy cancer treatment castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer metformin mHSPC neuroendocrine prostate cancer oncology oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals STAMPEDE trial STAT3 STEAP1 T-cell therapy theranostics treatment resistance
Latest Posts
- Update on CLS-1025: Precision T Cell Engager Phase 1 Study Expected in Early 2025 January 17, 2025
- UMass Scientists Develop Novel Bacteria-Based Cancer Therapy January 16, 2025
- Harnessing PROTAC Technology: A Novel Approach to Targeting ERG in Prostate Cancer January 15, 2025
- VIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer January 14, 2025